N-(Butan-2-YL)-6-[methyl(3-methylphenyl)sulfamoyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(Butan-2-YL)-6-[methyl(3-methylphenyl)sulfamoyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide
• 英文别名: N-butan-2-yl-6-[methyl-(3-methylphenyl)sulfamoyl]-4-oxo-1H-quinoline-3-carboxamide
• 化学式: C₂₂H₂₅N₃O₄S
• 分子量: 427.5
• InChiKey: QXFCZBCZKQIZGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Compositions and methods for treating disorders associated with salt or fluid retention
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2671584A2

  公开（公告）日：2013-12-11

  Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.

  本文描述了降低患者发生与体液和/或盐潴留有关的疾病的风险或治疗这种疾病的方法。这些方法包括向患者施用选自以下几种的制剂：a) 减少肠道钠吸收的制剂；b) 增加肠道阴离子分泌的制剂；或 c) 既减少肠道钠吸收又增加肠道阴离子分泌的制剂。
• COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF
  申请人：The Regents of the University of California

  公开号：EP1765347A2

  公开（公告）日：2007-03-28
• EP1765347A4
  申请人：——

  公开号：EP1765347A4

  公开（公告）日：2008-10-01
• COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2152266A1

  公开（公告）日：2010-02-17
• Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080319008A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.